Pharmafile Logo

Glaucoma in perspective

A black background with coloured shapes in the foreground and the title: Using generative AI in healthcare comms - our promise to our clients

Using generative AI in healthcare comms – our promise to our clients

It’s safe to say one of the hottest topics of 2023 has been ChatGPT and the launch of other Generative AI-driven applications. So, we’re sharing our promises, so that when...

Cuttsy + Cuttsy

EU flag

EC approves Blueprint’s Ayvakyt as first treatment for rare haematological disorder

The therapy targets the primary underlying cause of indolent systemic mastocytosis

- PMLiVE

Bristol Myers Squibb’s Sotyktu accepted by SMC for plaque psoriasis

More than 133,520 people in Scotland are affected by the inflammatory condition

- PMLiVE

Women’s Health Faces Some Difficult Headwinds. Here’s How We Can Move Forward

When it comes to women’s health, “we are a bit behind — almost where oncology was 20 years ago and neuroscience was about 10 years ago,” says Sandra Milligan, Head...

Medscape Education

- PMLiVE

Bristol Myers Squibb gains rights to SystImmune’s ADC candidate for up to $8.4bn

BL-B01D1 has shown promise against a range of solid tumours including lung cancer

- PMLiVE

Almirall and etherna partner to develop mRNA-based therapies for severe skin diseases

Dermatological diseases are estimated to affect 1.8 billion people worldwide

- PMLiVE

FDA grants fast track designation to Candel’s immunotherapy in pancreatic cancer

The disease is the fourth leading cause of cancer-related death in the US, accounting for 3.3% of new cancer cases

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links